No Data
Eyepoint Pharmaceuticals Granted U.S. Patent #12043664: Methods For Treating Vascular Leak Syndrome And Cancer
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target
TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
TD Cowen analyst Tyler Van Buren maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $30
H.C. Wainwright analyst Yi Chen maintains $EyePoint Pharmaceuticals(EYPT.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 24.
No Data